# Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial

> **NCT05763992** · PHASE2 · UNKNOWN · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 145 (estimated)

## Conditions studied

- Breast Cancer
- Triple Negative Breast Cancer
- Dietary Exposure
- Fasting

## Interventions

- **DIETARY_SUPPLEMENT:** Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B)

## Key facts

- **NCT ID:** NCT05763992
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-15
- **Primary completion:** 2025-05-15
- **Final completion:** 2026-05-15
- **Target enrollment:** 145 (ESTIMATED)
- **Last updated:** 2023-05-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05763992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05763992, "Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05763992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*